CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 50 enrolled
Drug / intervention
Sunitinibdrug
Likely dose
Sunitinib 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00589784
NCT00589784Phase 2Completed
CompareCT.gov

Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma

Memorial Sloan Kettering Cancer Center·interventional·Posted Jan 10, 2008·Updated Jan 25, 2016

In Brief

A Phase 2 clinical trial evaluating Sunitinib for CNS Cancer and 4 related conditions. Completed, enrolled 50 participants across 6 sites.

Detailed Summary

The purpose of this study is to find out what effects, good and/or bad, sunitinib has on patients and their tumors. At this time, no drugs are routinely used to treat meningioma, hemangioblastoma or hemangiopericytoma. Only surgery and radiation therapy are known to be useful. Sunitinib is a drug approved for advanced kidney cancer. Sunitinib is also being studied for other tumors. It may be useful in the treatment of brain tumors because it can prevent formation of new blood vessels that allow tumor cells to survive and grow.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCNS Cancer, Meningioma, Intracranial Hemangiopericytoma, Hemangioblastoma, Neurofibromatosis
CountriesUnited States
CollaboratorsDana-Farber Cancer Institute, University of Virginia, University of Pittsburgh, Pfizer

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 10, 2008
Enrollment StartOct 1, 2007
Primary CompletionOct 1, 2014
TodayJul 2, 2026
Enrollment to primary: 7 yearsPosted 18.5 years ago

Interventions

Sunitinibdrug

The study drug will be administered on an outpatient basis. The starting dose will be 50 mg daily for 28 days (4 consecutive weeks) followed by 14 days off for patients not on CYP3A4 inducers or inhibitors. A cycle equals 42 days.